Aurora-Miha Trifanov
FDA investigator
Appears on 2 documents from 2016 to 2020, mostly at sites in Michigan. Most often cites time limitations on production (21 CFR 211.111).
- 2
- Documents on file
- 1.5
- Observations per 483
- 2016
- First seen
- 2020
- Most recent
What they cite most
From 3 observations- 21 CFR 211.111Time limitations on production1
- 21 CFR 211.80(a)General requirements1
- 21 CFR 211.94Drug product containers and closures1
Activity by year
2016: 1, 2020: 1
Where
Michigan 2
Often inspects with
Is Aurora-Miha Trifanov coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2020-05-30 | 483 Caraco Pharmaceutical Laboratories, Ltd.May 30, 2020 · Detroit, Michigan | Detroit, Michigan | 1 | |
| 2016-11-21 | 483 King Pharmaceuticals, LLCNov 21, 2016 · Rochester, Michigan | Rochester, Michigan | 2 |
About this profile
What does Aurora-Miha Trifanov inspect?
Aurora-Miha Trifanov appears on 2 documents on file covering 2 sites, mostly in Michigan.
What do they cite most often?
21 CFR 211.111 (time limitations on production), followed by 21 CFR 211.80(a) and 21 CFR 211.94.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Aurora-Miha Trifanov is dated May 30, 2020.